Drug Discovery World

APRIL 30, 2024

This is essential to its use as a therapeutic agent and gives the technology a vast versatility making it suitable to treating a wide range of diseases – especially those that have high protein expression. mRNA-based approaches can produce proteins / peptides by using protein synthesis which is processed in a transfected cell 1.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Drug Discovery World

NOVEMBER 9, 2023

Novel approaches This session will feature two luncheon presentations: Nicholas Field, Principal Scientist, Purification Development, Lonza, on: ‘Tailored CMC solutions to overcome the challenges in bispecific, Fab and Fc-fusion protein development programs’. The session ends with two presentations and two luncheon presentations.

Engineering 130

Engineering Therapies Protein Production Science 130

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52